AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Sat, 19 October 2013 - Wed, 23 October 2013
June 3, 2013
Pasi Janne, MD PhD, Belfer Institute Scientific Director, senior auhor on New England Journal of Medicine article on study of new treatment of NSCLC patients with tumors harboring normal ALK gene.
In the News
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.
Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.